Elcelyx's Metformin DR meets Phase IIb diabetes endpoint

Elcelyx Therapeutics Inc. (San Diego, Calif.) said Metformin DR met the primary endpoint in a Phase IIb trial to treat Type II diabetes. The delayed-release, enteric-coated tablet formulation of metformin significantly reduced HbA1c at week 16 vs. placebo. The candidate also significantly reduced fasting plasma glucose vs. placebo.

Elcelyx said the readout supports Metformin DR's development to treat Type II diabetes patients with renal impairment in whom metformin use is contraindicated, and for patients who do not tolerate existing metformin formulations...